News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GammaCan International, Inc. (GCAN.OB) Enters into Vitiligo Plasma Supply Agreement with DCI Biologicals



10/1/2007 9:45:23 AM

KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, today announced the signing of a second plasma supply agreement. Under this second agreement, DCI Biologicals, Inc. will collect plasma from Vitiligo donors for the manufacture of VitiGam™, GammaCan’s lead product in development for the treatment of Stage III and IV melanoma.

Read at BioSpace.com


comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES